A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. - Wikidata - wikimedia - TriplyDB

A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.

A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.

http://www.wikidata.org/entity/Q33587028

about

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy Trial Watch:: Oncolytic viruses for cancer therapy Virotherapy: cancer gene therapy at last?Oncolytic virotherapy for pediatric malignancies: future prospects Trial Watch-Oncolytic viruses and cancer therapy Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.Designing Herpes Viruses as Oncolytics.Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment Development of an HSV-1 neutralization test with a glycoprotein D specific antibody for measurement of neutralizing antibody titer in human sera Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.Trial Watch: Immunotherapy plus radiation therapy for oncological indications.Worldwide circulation of HSV-2 × HSV-1 recombinant strains.Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations.Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas.Current status of clinical trials assessing oncolytic virus therapy for urological cancers.Viral vectors for therapy of neurologic diseases.Oncolytic Virotherapy for the Treatment of Malignant Glioma.Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes Viruses Investigational new drugs for brain cancer.Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.Immunotherapy approaches in the treatment of malignant brain tumors.Immune System, Friend or Foe of Oncolytic Virotherapy?Gene Therapy in the Nervous System: Failures and Successes.Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies.Activating Peripheral Innate Immunity Enables Safe and Effective Oncolytic Virotherapy in the Brain.The history of neurosurgery at the University of Alabama at Birmingham.Review: Oncolytic virotherapy, updates and future directions.New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.From Benchtop to Bedside: A Review of Oncolytic Virotherapy.Stability and anti-tumor effect of oncolytic herpes simplex virus type 2.Viral Vectors in Gene Therapy.Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma

P2860

Q26775030-4AB4F471-68A7-491A-A87F-52FD74FF5FC2 Q26998111-A1BA2826-CD8E-4CE9-9D5C-BC441EABCE80 Q27021951-8CBB76FB-ECE7-427C-B707-51AE90A6A236 Q28066228-82344894-DABA-4030-9E4E-A6296452EC10 Q28069358-625F8E71-7605-48ED-9F2F-623C87EDF450 Q28072347-D976F412-9B2A-4CCF-B642-A1BD07A7EC53 Q35657822-7432F83F-6DD2-44BA-9C87-808CBA98F6A9 Q36109704-59979057-4C51-48C7-92A9-CDEDB83CF724 Q36142487-6D7BBFCB-4669-49F0-9AF2-173ED9FFA41C Q36493813-02F40392-F3B6-4887-AB1D-16609117C5CB Q36549443-2CE08415-45CC-4B14-8299-34D3D28CE0E1 Q36658280-52C45022-AFB2-473A-9C12-8BC335E7F6A0 Q36700993-E8254DF1-7173-454A-8922-906C09B1A5E9 Q37064326-084C20F0-1BED-4793-8E15-59C7307D1E2E Q37308207-4F268914-87CC-4248-845B-21D3A6A34FD2 Q37695200-AC880DFA-DCBA-40B0-9610-47B24902ECB5 Q38600417-060927D7-4A7D-4F4F-8C66-59B014B0CD8B Q38645128-7AC828EA-7D36-40DB-B327-959AF81A33F4 Q38715077-9E1DFB34-2B60-43D7-8939-FA94048D00E6 Q38741837-1C496B8D-6DDF-4C73-8AB8-E54131923614 Q38746238-E3824651-3F2C-45E9-89D3-1F72FDE35048 Q38749871-7B6D720A-0865-4BFC-9F49-D1A39C3C43FA Q38795324-5E47516F-47C5-4B8B-AC98-E05CA9BB1F42 Q38832510-52968CC8-858C-4C82-AD86-929E148F4A5E Q38966483-3C91F2FB-4DEC-4249-B53E-DCCB1516CBE2 Q39016790-C46F5999-452E-4B41-B441-15CBFCE4B9F5 Q39355854-24F76AC5-5667-46D6-94B5-483376A589C2 Q40070708-3D19DD16-2795-4D7D-A87B-8B78CF662190 Q40284855-D8925E5C-963A-44AD-87CF-F48E8A4C2C4F Q41684403-E81E2DDC-67EE-44F3-BDA4-958CF40CD116 Q42795549-49E40BD8-27B5-4F8B-AB2D-68C02817CA30 Q45775844-0F36090E-D932-4B11-B53D-F948060D932E Q47160989-043E0821-2BE7-4EE2-882F-F485E9D27664 Q50056861-2566D671-D2C4-4F89-9393-6345A9083FF0 Q52365121-3EF12B92-6F83-43E3-9E07-8FC6D74100BD Q53272922-A6F88B0A-83B8-46A7-9377-51F4A549CE0C Q54974000-18CB0EA4-6C22-42E4-8068-2E1B40253059 Q55408780-162A2C96-C083-4666-B5D3-634BDBE53B3F Q58734384-1AC701D1-C37D-4EF7-BE00-C709F439D1FA Q59117175-06478864-5210-45A8-B96C-6E49CA8E2518

P2860

A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.

http://www.wikidata.org/entity/Q33587028

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A phase 1 trial of oncolytic H ...... ty and radiographic responses.

@ast

A phase 1 trial of oncolytic H ...... ty and radiographic responses.

@en

A phase 1 trial of oncolytic H ...... ty and radiographic responses.

@nl

type

label

A phase 1 trial of oncolytic H ...... ty and radiographic responses.

@ast

A phase 1 trial of oncolytic H ...... ty and radiographic responses.

@en

A phase 1 trial of oncolytic H ...... ty and radiographic responses.

@nl

prefLabel

A phase 1 trial of oncolytic H ...... ty and radiographic responses.

@ast

A phase 1 trial of oncolytic H ...... ty and radiographic responses.

@en

A phase 1 trial of oncolytic H ...... ty and radiographic responses.

@nl

P1433

Q33587028-E175AAD7-BBAB-4393-BBB5-F79DED80D9AA

P1476

Q33587028-45C13CED-BFB7-4B67-B071-667DED9BA2D3

P2093

Q33587028-0092558E-C7DA-43C3-A3DE-DC34DB2599E1

Q33587028-1B0EC9E6-087C-4954-AB0F-6D8C7D941A37

Q33587028-3B52744A-7380-47E0-B2D0-87C6B2A69181

Q33587028-4AD1E32A-B8E8-4E2F-96D9-F05CF29FB01F

Q33587028-57F815EB-8D0F-41DF-904F-54F6F19B4D59

Q33587028-69E050B7-152A-4BC8-B9DD-2BEE91E00E93

Q33587028-6B782C4E-A3E0-4D4D-ACFF-CCD93CDEDBBA

Q33587028-810BE73A-8056-4669-A5FA-1E078A5BC452

Q33587028-85C87C89-90D0-4BC1-A956-BFC726857BDC

Q33587028-85E5BDD4-82EF-4D2E-AEE9-473867F8E946

P2860

Q33587028-055E5712-9948-4F9B-A487-4B8DD29D4988

Q33587028-1A114FEA-8229-40C2-9994-917CD861B188

Q33587028-2DACAEA6-2817-4E0F-BD5D-F994B9169F2D

Q33587028-444813B9-5112-409F-AAEC-C579A0794CBF

Q33587028-4461A9E0-A881-4DD5-BBAC-CC6B30B3B68E

Q33587028-4E1EF4C3-A7B5-4705-BB20-F2CA20DB7759

Q33587028-4E8F152E-D41B-45CC-8DB0-70ED2E7DAC81

Q33587028-556DFA99-B1EA-48BE-8F16-72B61930EC76

Q33587028-686572AD-DC4E-4D45-9E08-AF78CDFD45AC

Q33587028-8ECA1651-C3E1-4B39-A070-2BD73F2DB1A2

P304

Q33587028-5FD0DD9F-0499-48B1-A2CE-851FD7D891AD

P31

Q33587028-8AB7B17B-5638-4BDC-B094-90F212AD6125

P356

Q33587028-38FBA46C-76CF-4A11-BFA9-95DD8E3A3907

P433

Q33587028-48D28D8F-DF14-4499-BAFF-8B870F600570

P478

Q33587028-86F264F5-D9C2-4F9A-BD14-46E1FB43BBAD

P50

Q33587028-1B1CBCB4-8427-4E0D-9F2A-5B93D632641E

Q33587028-46F42A0E-C012-491D-AC15-A22CFB57D08D

Q33587028-7EFDC76D-2B71-417F-AD5D-DDC85F88D4E8

P577

Q33587028-CF315FB6-0B5D-4D97-9599-B0D4AF686338

P5875

Q33587028-7CC9EBD6-C81D-44BA-B831-EF1BBC6A493F

P698

Q33587028-75270913-3ABF-4233-8495-ECBB630BF684

P921

Q33587028-D365F4BE-43BB-4FB5-B65F-BCCCAED2C879

P932

Q33587028-DA036188-7D6A-4E26-877C-BB7F9AB116BA

P356

P1433

Molecular Therapy

P1476

A phase 1 trial of oncolytic H ...... ety and radiographic responses

@en

P2093

Alan Cantor

http://www.w3.org/2001/XMLSchema#string

Alfred D Lakeman

http://www.w3.org/2001/XMLSchema#string

Anette Knoll

http://www.w3.org/2001/XMLSchema#string

Bonita S Agee

http://www.w3.org/2001/XMLSchema#string

G Yancey Gillespie

http://www.w3.org/2001/XMLSchema#string

Hui-Chien Kuo

http://www.w3.org/2001/XMLSchema#string

Jacqueline N Parker

http://www.w3.org/2001/XMLSchema#string

James M Markert

http://www.w3.org/2001/XMLSchema#string

Jennifer M Coleman

http://www.w3.org/2001/XMLSchema#string

John B Fiveash

http://www.w3.org/2001/XMLSchema#string

P2860

Seroepidemiology of Herpes Simplex virus type 1 and 2 in Western and Southern Switzerland in adults aged 25-74 in 1992-93: a population-based study

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.

Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM

Genetically engineered HSV in the treatment of glioma: a review.

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.

P304

1048-1055

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2014.22

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Ralph Weichselbaum

Cheryl Ann Palmer

P577

2014-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260393163

http://www.w3.org/2001/XMLSchema#string

P698

24572293

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4015243

http://www.w3.org/2001/XMLSchema#string